PGHL · NSE
Procter & Gamble Health Limited
₹5,503.5
+1.27% (+₹69)
Prev. close
₹5,434.5
Volume
5,754
Delivery %
54.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Milind Vasant Thatte M.B.A.
Headquarters
Mumbai
Employees
1,276
Website
pghealthindia.comExchange
View on NSE ↗Key stats
Market cap
₹9,135.47 Cr
P/E ratio (TTM)
25.6
Dividend yield
2.85%
EPS (TTM)
₹215.21
Beta (1Y · daily vs NIFTY 50)
0.52
Beta (5Y · monthly vs NIFTY 50)
0.36
Shares float
1.19 Cr
EPS · quarter ended Jun 2026
₹57.92
Financial Performance
01 · Financials
Revenue for Jun 2021–Jun 2021 is as filed with BSE (standalone), and the first plotted growth figure is computed against Jun 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 2.0% on Jun 2022. FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Fiscal year-end moved from June to March between Jun 2024 and Mar 2025; the company's transition period bridged the two calendars, so no intermediate 12-month year exists — the "missing" column is a period that never was, not a data gap. Growth at Mar 2026 is annualized over the 21-month transition period (vs Jun 2024), not a standard 12-month year-over-year rate.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
Fiscal year-end moved from June to March between Jun 2024 and Mar 2026; the company's transition period bridged the two calendars, so no intermediate 12-month year exists — the "missing" column is a period that never was, not a data gap. Growth at Mar 2026 is annualized over the 21-month transition period (vs Jun 2024), not a standard 12-month year-over-year rate.
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ₹1,008.73 Cr | ₹1,092.04 Cr | ₹1,205.86 Cr | ₹1,129.49 Cr | — | ₹1,407.97 Cr | |
| EBITDA | ₹264.12 Cr | ₹280.87 Cr | ₹343.07 Cr | ₹301.44 Cr | — | ₹474.00 Cr |
| ₹176.80 Cr | ₹192.52 Cr | ₹229.47 Cr | ₹200.98 Cr | — | ₹326.91 Cr | |
| Diluted EPS | ₹106.5 | ₹116 | ₹138 | ₹121 | — | ₹196.94 |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ₹986.16 Cr | ₹888.12 Cr | ₹1,101.19 Cr | ₹794.36 Cr | ₹794.20 Cr | ₹841.35 Cr | |
| ₹7.61 Cr | ₹2.83 Cr | ₹12.00 Cr | ₹9.56 Cr | — | ₹9.29 Cr | |
| Stockholders' equity | ₹703.71 Cr | ₹616.49 Cr | ₹750.89 Cr | ₹538.24 Cr | ₹536.96 Cr | ₹524.55 Cr |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Trade receivables, Cash & equivalents, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ₹247.26 Cr | ₹169.52 Cr | ₹236.00 Cr | ₹228.29 Cr | ₹168.69 Cr | ₹337.79 Cr | |
| Investing cash flow | ₹-32.27 Cr | ₹-25.54 Cr | ₹-21.50 Cr | ₹-6.87 Cr | ₹9.59 Cr | ₹1.26 Cr |
| ₹-386.63 Cr | ₹-288.63 Cr | ₹-98.47 Cr | ₹-418.11 Cr | ₹-234.74 Cr | ₹-343.92 Cr | |
| Capital expenditure | — | ₹-37.92 Cr | ₹-42.48 Cr | ₹-21.73 Cr | ₹-8.60 Cr | ₹-15.51 Cr |
| End cash position | ₹464.05 Cr | ₹319.40 Cr | ₹435.42 Cr | ₹238.73 Cr | ₹182.27 Cr | ₹177.40 Cr |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Depreciation & amortization, Change in working capital, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 51.82% |
| Public | 48.18% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Procter & Gamble Health Limited | ₹8,963.67 Cr | ₹5,411.5 | 25.1 | 17.09 | 62.3% | 0.02 | +22.6% | -13.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Read This Before Considering Procter & Gamble Health Limited (NSE:PGHL) For Its Upcoming ₹45.00 Dividend
Procter & Gamble Health Limited is set to go ex-dividend for its ₹45.00 per share payment in three days. While the company's dividend payout ratio from earnings is typical, it paid out 106% of its free cash flow last year, which raises concerns about dividend sustainability. The company has shown strong earnings and dividend growth over the past five to ten years.